15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Genmab AS, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $32.00 to $48.00, a moderate spread. The average target of $39.36 sits 36% above the current $28.98. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.35 next quarter toward $1.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Genmab AS.
As of Jul, 6 of 7 firms rate GMAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GMAB EPS & revenue forecast
EPS · NEXT QUARTER
$0.35
Range $0.30 – $0.37 · 5 analysts · -47% YoY
Next period, 5 analysts expect Genmab AS to earn $0.35 a share (range $0.30 – $0.37), versus $0.65 a year earlier. Full-year consensus is $1.32, growing to $1.88 the year after.
REVENUE · NEXT QUARTER
$7.6B
Range $7.2B – $9.0B · 5 analysts · +15% YoY
Revenue is expected to reach $7.6B (range $7.2B – $9.0B), +15.3% year-over-year. Full-year consensus is $28.2B, rising to $33.1B next year.
Top analysts covering Genmab AS
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GMAB.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$40.00+38.0% to target
Overall win rate
55%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$40.00+38.0% to target
Overall win rate
37%
+ Follow
#3
Asthika Goonewardene
Truist Securities
Buy
$48.00+65.6% to target
Coverage
—
+ Follow
#4
EF
Eva Fortea Verdejo
Wells Fargo
Buy
$40.00+38.0% to target
Coverage
—
+ Follow
#5
Judah Frommer
Morgan Stanley
Hold
$33.00+13.9% to target
Coverage
—
+ Follow
GMAB stock forecast FAQ
What is GMAB's average 12-month price target?+
The 7 analysts with a live target average $39.36 for Genmab AS over the next 12 months, ranging from a $48.00 high to a $32.00 low.
Is GMAB stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GMAB?+
The Street-high target is $48.00 (Truist Securities), and the Street-low is $32.00 (Wolfe Research). The average of all 7 active targets is $39.36.
How many Wall Street analysts cover GMAB?+
7 analysts have an active rating on Genmab AS, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering GMAB?+
Among analysts who currently cover GMAB, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $40.00 target.
What is Genmab AS's projected EPS for next quarter?+
The consensus estimate is $0.35 per share (range $0.30 – $0.37) across 5 analysts. Full-year EPS is projected at $1.32, rising to $1.88 the following year.
How much revenue is Genmab AS expected to report next quarter?+
Consensus revenue is $7.6B (range $7.2B – $9.0B). Full-year revenue is projected at $28.2B, growing to $33.1B next year.
Have analysts been upgrading or downgrading GMAB lately?+
As of Jul, 6 of 7 firms rate GMAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GMAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
